Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Kidney transplant recipient~2. Age 2-17 years, inclusive, at the time of first study dose~3. Estimated GFR (eGFR) ≥30 ml/min/1.73m2, with stable allograft function as indicated by \<20% change in serum creatinine in the previous 30 days~4. Stable immunosuppressive regimen, as indicated by \<10% change in dosage (in mg/kg) in these medications, within the 14 days prior to enrollment~5. Systolic BP \>90th percentile for age, gender, and height, necessitating initiation or addition of an antihypertensive medication~6. For females of child-bearing potential, a negative serum pregnancy test prior to initial dosing and agreement to practice appropriate contraceptive measures, including abstinence, from the time of the initial pregnancy testing through the remainder of the study (30 days after last administration of investigational agents).~Exclusion Criteria:~1. History of anaphylaxis attributable to lisinopril or other angiotensin-converting enzyme inhibitor (ACEI) agents (e.g.,enalapril, ramipril, quinapril)~2. History of anaphylaxis attributable to iohexol or an iodine hypersensitivity~3. Use of an angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker, or renin antagonist within 30 days prior to enrollment~4. Stage 2 hypertension defined as the \>99th percentile for age, height and gender + 5 mm Hg~5. Blood Potassium value \> 6.0 milliequivalent / liter (mEq/L) (as determined at the screening visit)~6. Previous participation in this study~7. Physician concern that the participant may not adhere to the study protocol, based on prior behavior~8. Current plasmapheresis treatment~9. History of angioedema~10. Pregnancy

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose: Lisinopril (Type: EXPERIMENTAL): Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day
- Medium Dose: Lisinopril (Type: EXPERIMENTAL): Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day
- High Dose: Lisinopril (Type: EXPERIMENTAL): Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).